Isofol Medical

The information in the press release is intended for investors.

The number of shares and votes in Isofol Medical AB (publ) has changed due to the recently completed rights issue including the overallotment issue and set-off issue carried out as compensation in shares to guarantors (for further information, see the company’s press release on July 4, 2025). Through the new share issues, which were registered with the Swedish Companies Registration Office on July 15, 2025, the number of shares and votes in Isofol increased with a total of 119,591,784. Today, on the last trading day of the month, there are in total 281,107,224 shares and votes in Isofol.

For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer 
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56

Margareta Hagman, CFO
E-post: margareta.hagman@isofolmedical.com
Phone: +46 (0) 738 73 34 18

This is information that Isofol Medical AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on 31 July 2025, at 08:00 CEST.

About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with a new dosing regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com